Please login to the form below

Not currently logged in
Email:
Password:

QuintilesIMS changes its name to IQVIA

Firm will focus on human data science solutions

IQVIAA year after its initial launch as QuintilesIMS, the pharma service provider has re-launched as IQVIA.

Its new name maintains parts of its original formation, with the ‘I’ representing IMS and the ‘Q’ taken from Quintiles.

However, the latter and newest part of the name - ‘via’  - is representative of “seeking to inspire and ignite real change via a new path forward”, explains Ari Bousbib, chief executive officer of IQVIA.

Bousbib added: “We launched as QuintilesIMS, then we built something transformational and that is how we became IQVIA.

“We aim to bring the potential of human data science to life to find better solutions for patients.”

The group has a slightly different offering from when it first became QuintilesIMS, which was due to a mega-merger of healthcare services provider Quintiles and information and technology group IMS, offering pharma clients an end-to-end clinical and commercial package.

Now, the newly-named group will provide solutions to healthcare companies through analytics, data science and human science, claiming expertise in research and development, real-world value and outcomes, commercialisation and technologies.

Article by
Gemma Jones

10th November 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics